Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
独立董事关于对公司累计和当期担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of 瑞康医药股份有限公司 regarding the company's cumulative and current guarantee situation. It references compliance with regulatory notice 证监发[2005]120号 about external guarantees by listed companies. The content focuses on the company's guarantee activities, board and shareholder meeting approvals, and assurance of no illegal guarantees. The document is signed by independent directors and dated April 25, 2018. It is a standalone audit-related statement concerning guarantees and compliance, not a full annual report or financial statement. It does not contain comprehensive financial data or management discussion but is a regulatory compliance and audit-related opinion. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive independent opinion and regulatory compliance content, not merely an announcement or certification letter, so it is not RNS or RPA. FY 2017
2018-04-25 Chinese
关于公司2017年度募集资金存放与使用情况的鉴证报告
Capital/Financing Update Classification · 95% confidence The document is titled "2017 年度募集资金存放与使用情况的专项报告" which translates to "2017 Annual Special Report on the Deposit and Use of Raised Funds". It details the amounts of funds raised through non-public stock issuance in 2012 and 2015, the usage of these funds, the management and supervision of the raised funds, and compliance with regulatory requirements. It includes detailed tables showing the use of funds, approvals by the board, and audit confirmations. The document is a specialized report focusing on the management and use of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). It is not a full annual report, earnings release, or audit report, but a specific report on fundraising and capital usage. The document length is substantial (over 13,000 characters) and contains detailed financial data related to capital usage, not just an announcement or summary. Therefore, the best fitting classification is CAP (Capital/Financing Update).
2018-04-25 Chinese
国金证券股份有限公司关于公司2017年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent verification opinion from Guojin Securities Co., Ltd. regarding the 2017 annual fundraising funds deposit and usage situation of Ruikang Pharmaceutical Co., Ltd. It references regulatory frameworks such as the Securities Issuance and Listing Sponsorship Business Management Measures and Shenzhen Stock Exchange guidelines. The document includes extensive financial data on fundraising amounts, usage, bank accounts, and compliance with regulations. It is a specialized audit or verification report focused on the use and management of raised funds, not a full annual report or earnings release. The presence of audit report numbers and the nature of the content indicate it is an audit-related document verifying compliance and proper use of funds. Therefore, the document fits best under the category of Audit Report / Information (AR). The document length (over 13,000 characters) and detailed financial data support this classification rather than a brief announcement or regulatory filing. FY 2017
2018-04-25 Chinese
2017年年度报告
Annual Report Classification · 100% confidence The document is titled "瑞康医药股份有限公司 2017 年年度报告全文" which translates to "Realcan Pharmaceutical Co., Ltd. 2017 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the full fiscal year 2017, management discussion and analysis, business overview, financial statements, and governance information. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of detailed financial figures, business analysis, and management commentary confirms this is the full annual report for the fiscal year 2017. Therefore, the appropriate classification is Annual Report (10-K). FY 2017
2018-04-25 Chinese
关于公司2017年度控股股东及其他关联方资金占用情况的专项说明
Capital/Financing Update Classification · 95% confidence The document is titled '2017 年度募集资金存放与使用情况的专项报告' which translates to '2017 Annual Special Report on the Deposit and Use of Raised Funds'. This indicates it is a report specifically about the use and storage of funds raised by the company in 2017. The content length is short (727 characters), and it is a focused report on fundraising usage rather than a general annual report or earnings release. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. There is no indication that this is an announcement of a report or a certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2018-04-25 Chinese
独立董事2017年度述职报告（于建青）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2017 Annual Work Report" for Ruikang Pharmaceutical Co., Ltd. It details the independent director's attendance at board meetings, opinions expressed, investigations conducted, committee roles, investor protection efforts, and training during the year 2017. The content is a narrative report on the director's duties and activities over the year rather than a financial report or regulatory filing. It is not an Annual Report (10-K), Audit Report, or any financial statement. It is also not a simple announcement or certification. The document fits best as Board/Management Information (MANG) because it relates to the activities and reports of a board member (independent director) about their role and oversight during the year.
2018-04-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.